LFB S.A. Receives Go Ahead From Data Monitoring Committee to Expand The Global PERSEPT Phase 3 Program of LR769 in Hemophilia A or B Patients with Inhibitors

PARIS, France, March 24, 2015 —LFB SA announced today, through its rEVO Biologics subsidiary, that after the planned interim analysis of the PerSept 1 safety and efficacy data by the independent Data Monitoring Committee (DMC), the DMC recommended that the study proceed as planned and also that LFB should expand the global PerSept Phase 3 program.